Autolus Therapeutics PLC
AUTL
View Detailed Chart
1.270USD
+0.060+4.96%
Close 03/30, 16:00（ET）Quotes delayed by 15 min
49.26MMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
+4.96%
5 Days
-9.29%
1 Month
-23.95%
6 Months
-22.09%
Year to Date
-36.18%
1 Year
-23.49%
View Detailed Chart
TradingKey Stock Score of Autolus Therapeutics PLC
Currency: USD Updated: 2026-03-27Key Insights
Autolus Therapeutics PLC's fundamentals are relatively stable, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 36 out of 391 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 8.39.In the medium term, the stock price is expected to trend down.Despite a very weak market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Autolus Therapeutics PLC's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Positive
Autolus Therapeutics PLC Highlights
StrengthsRisks
Autolus Therapeutics plc is a United Kingdom-based early commercial-stage biopharmaceutical company developing programmed T cell therapies for the treatment of cancer and autoimmune diseases. The Company has an approved commercial product, AUCATZYL, for the treatment of adult patients with r/r B-ALL. Using a suite of proprietary and modular T cell programming technologies, it is also developing five programs in seven hematological and solid tumor indications and one autoimmune indication. It is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize target cells, break down their defense mechanisms and attack and eliminate these cells. Its product pipeline includes obe-cel (ALLCAR19), obe-cel (CAROUSEL), AUTO1/22 (CARPALL), AUTO4 (LibrA T1), AUTO6 (MAGNETO), AUTO5, AUTO8 (MCARTY) and AUTO9. AUTO4 and AUTO5 are two programmed T cell therapies for the treatment of peripheral T-cell lymphoma targeting TRBC 1 and TRBC 2.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 4339.81% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 75.39M.
Overvalued
The company’s latest PE is -1.12, at a high 3-year percentile range.
Institutional Buying
The latest institutional holdings are 194.47M shares, increasing 0.07% quarter-over-quarter.
Held by Invesco
Star Investor Invesco holds 51.64K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.62.
Analyst Rating
Based on
12
analysts
Buy
Current Rating
8.718
Target Price
+575.83%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Autolus Therapeutics PLC News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Autolus Therapeutics PLC Info
Autolus Therapeutics plc is a United Kingdom-based early commercial-stage biopharmaceutical company developing programmed T cell therapies for the treatment of cancer and autoimmune diseases. The Company has an approved commercial product, AUCATZYL, for the treatment of adult patients with r/r B-ALL. Using a suite of proprietary and modular T cell programming technologies, it is also developing five programs in seven hematological and solid tumor indications and one autoimmune indication. It is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize target cells, break down their defense mechanisms and attack and eliminate these cells. Its product pipeline includes obe-cel (ALLCAR19), obe-cel (CAROUSEL), AUTO1/22 (CARPALL), AUTO4 (LibrA T1), AUTO6 (MAGNETO), AUTO5, AUTO8 (MCARTY) and AUTO9. AUTO4 and AUTO5 are two programmed T cell therapies for the treatment of peripheral T-cell lymphoma targeting TRBC 1 and TRBC 2.
Ticker SymbolAUTL
CompanyAutolus Therapeutics PLC
CEOItin (Christian Martin)
Websitehttps://www.autolus.com/
Related Instruments
+0.96%
+1.56%
+0.85%
+2.90%
-1.28%
+1.78%
+1.47%
+0.07%
+0.00%
+2.70%
-2.08%
-0.13%
+0.72%
+2.03%
+2.33%
0.00%
+1.57%
-0.13%
+2.63%
+2.01%Popular Symbols
246.630
-2.170 (-0.87%)
165.170
-2.350 (-1.40%)
67967.040
+1345.640 (+2.02%)
251.670
-23.670 (-8.60%)
2072.610
+51.910 (+2.57%)
355.280
-6.550 (-1.81%)
4585.570
+74.790 (+1.66%)
101.201
-3.061 (-2.94%)
1.147
+0.001 (+0.09%)
159.620
-0.039 (-0.02%)
